U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H14NO3.K
Molecular Weight 331.407
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXAPROZIN POTASSIUM

SMILES

[K+].[O-]C(=O)CCC1=NC(=C(O1)C2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=QTAQWNSMRSLSCG-UHFFFAOYSA-M
InChI=1S/C18H15NO3.K/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14;/h1-10H,11-12H2,(H,20,21);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula C18H14NO3
Molecular Weight 292.3087
Charge -1
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula K
Molecular Weight 39.0983
Charge 1
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Anti-inflammatory effects of Oxaprozin are believed to be due to inhibition of cylooxygenase in platelets which leads to the blockage of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Oxaprozin is a non-selective NSAID, with a cell assay system showing lower COX-2 selectivity implying higher COX-1 selectivity. Oxaprozin is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and to alleviate moderate pain.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
36.0 µM [IC50]
2.2 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DAYPRO
Primary
DAYPRO
Primary
DAYPRO

Cmax

ValueDoseCo-administeredAnalytePopulation
129 mg/L
1.2 g single, oral
OXAPROZIN plasma
Homo sapiens
174 mg/L
1.8 g single, oral
OXAPROZIN plasma
Homo sapiens
239 mg/L
1.2 g 1 times / day steady-state, oral
OXAPROZIN plasma
Homo sapiens
280 mg/L
1.8 g 1 times / day steady-state, oral
OXAPROZIN plasma
Homo sapiens
78.4 mg/L
0.6 g single, oral
OXAPROZIN plasma
Homo sapiens
103 μg/mL
1.2 g single, oral
OXAPROZIN plasma
Homo sapiens
109 μg/mL
1.2 g single, oral
OXAPROZIN plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
2240 mg × h/L
1.2 g single, oral
OXAPROZIN plasma
Homo sapiens
2970 mg × h/L
1.8 g single, oral
OXAPROZIN plasma
Homo sapiens
4210 mg × h/L
1.2 g 1 times / day steady-state, oral
OXAPROZIN plasma
Homo sapiens
4770 mg × h/L
1.8 g 1 times / day steady-state, oral
OXAPROZIN plasma
Homo sapiens
1290 mg × min/L
0.6 g single, oral
OXAPROZIN plasma
Homo sapiens
7042 μg × h/mL
1.2 g single, oral
OXAPROZIN plasma
Homo sapiens
7066 μg × h/mL
1.2 g single, oral
OXAPROZIN plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
54.9 h
1.2 g single, oral
OXAPROZIN plasma
Homo sapiens
47 h
1.8 g single, oral
OXAPROZIN plasma
Homo sapiens
41.4 h
1.2 g 1 times / day steady-state, oral
OXAPROZIN plasma
Homo sapiens
58.3 h
0.6 g single, oral
OXAPROZIN plasma
Homo sapiens
50 h
1.2 g single, oral
OXAPROZIN plasma
Homo sapiens
48 h
1.2 g single, oral
OXAPROZIN plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
0.21%
1.2 g single, oral
OXAPROZIN plasma
Homo sapiens
0.3%
1.8 g single, oral
OXAPROZIN plasma
Homo sapiens
0.46%
1.2 g 1 times / day steady-state, oral
OXAPROZIN plasma
Homo sapiens
0.82%
1.8 g 1 times / day steady-state, oral
OXAPROZIN plasma
Homo sapiens
0.13%
0.6 g single, oral
OXAPROZIN plasma
Homo sapiens

Doses

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as victim

PubMed

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Osteoarthritis Loading dose: 1200 mg to 1800 mg orally; not to exceed 26 mg/kg Maintenance dose: 1200 mg orally once a day Maximum dose: 1800 mg or 26 mg/kg orally per day, whichever is less, in divided doses
Route of Administration: Oral
In Vitro Use Guide
In arachidonic acid (AA)-induced rabbit platelet aggregation in vitro, oxaprozin exhibited a dose-dependent inhibitory effect with MIC 124.2 uM.
Substance Class Chemical
Record UNII
ML56O2Z92I
Record Status Validated (UNII)
Record Version